Shares of Summit Therapeutics surged 10.3% to $14.73 after The Lancet Oncology published full results from the company's flagship HARMONi trial, confirming that its experimental drug — a two-target antibody that blocks both a tumor-shielding protein and a blood-vessel growth signal — delivered median progression-free survival of 6.8 months versus 4.4 months for chemotherapy alone, with a hazard ratio of 0.52 and p<0.0001 . The question now: whether blockbuster clinical numbers can justify a company with zero revenue and a ~$10.7 billion market cap.
A 48% Reduction in Disease Worsening Sets the Stage for FDA Approval The hazard ratio of 0.52 means patients on ivonescimab were roughly half as likely to see their cancer progress at any given time — a striking margin in a lung cancer subgroup where traditional PD-1 therapies have not demonstrated clear benefit . Summit submitted its application for U.S. marketing approval, which the FDA accepted in January 2026; the target decision date is November 14, 2026 . That makes the next 80 days the most consequential in the company's history.
The Missing Piece: Survival Data Still Isn't Definitive Progression-free survival — how long before a tumor starts growing again — is not the same as living longer. Overall survival showed a favorable trend (median 16.8 months vs. 14 months, HR 0.79) but did not reach statistical significance . Updated overall survival data will be presented at the World Conference on Lung Cancer later in 2026 . Until that gap closes, skeptics have reason to question the durability of the benefit.
The Cash Burn Clock Is Ticking Summit is a late-stage oncology developer with no revenue, deeply negative margins, and return on equity below –200% . A $598.7 million cash balance looks solid, but quarterly operating expenses above $120 million give it roughly five to six quarters of runway. A planned $500 million equity raise adds dilution risk — meaning existing shareholders' stakes get smaller — even as it extends the financial lifeline .
The Keytruda Shadow: Huge Opportunity, Fierce Competition Ivonescimab is projected to reach $1.7 billion in global sales by 2030 , a fraction of Keytruda's dominance but transformative for Summit. Competition is real: by late 2027, rival two-target antibodies from Pfizer and Merck may be vying for approval . Short interest sits at 26.8% of shares outstanding — a sign that a sizable camp is betting the stock has run ahead of proven value.